Impact of the N348I Mutation in HIV-1 Reverse Transcriptase on Nonnucleoside Reverse Transcriptase Inhibitor Resistance in Non-Subtype B HIV-1

Ítems similars

• Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa
  per: Sutherland, Katherine A., et al.
  Publicat: (2015)
• Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial
  per: Sutherland, Katherine A., et al.
  Publicat: (2015)
• Correction: Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial
  per: Sutherland, Katherine A., et al.
  Publicat: (2016)
• Conformational Changes in HIV-1 Reverse Transcriptase Induced by Nonnucleoside Reverse Transcriptase Inhibitor Binding
  per: Sluis-Cremer, Nicolas, et al.
  Publicat: (2004)
• Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase
  per: Tachedjian, Gilda, et al.
  Publicat: (2001)